



REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FIRST QUARTER				
	2021	2020	% Change		
			Reported	Operational ⁽¹⁾	Currency
CONSUMER HEALTH SEGMENT ⁽²⁾					
<u>OTC</u>					
US	\$ 599	689	-13.0%	-13.0%	-
Intl	575	659	-12.8%	-16.6%	3.8%
WW	1,175	1,348	-12.9%	-14.8%	1.9%
<u>SKIN HEALTH / BEAUTY</u>					
US	634	659	-3.9%	-3.9%	-
Intl	529	458	15.7%	12.3%	3.4%
WW	1,163	1,117	4.1%	2.8%	1.3%
<u>ORAL CARE</u>					
US	163	176	-7.2%	-7.2%	-
Intl	254	219	16.0%	13.9%	2.1%
WW	417	395	5.7%	4.5%	1.2%
<u>BABY CARE</u>					
US	96	92	4.2%	4.2%	-
Intl	293	269	8.9%	11.3%	-2.4%
WW	389	361	7.7%	9.5%	-1.8%
<u>WOMEN'S HEALTH</u>					
US	3	4	-25.8%	-25.8%	-
Intl	219	228	-3.9%	-2.2%	-1.7%
WW	222	232	-4.3%	-2.6%	-1.7%
<u>WOUND CARE / OTHER</u>					
US	115	119	-3.0%	-3.0%	-
Intl	61	52	17.6%	14.2%	3.4%
WW	177	171	3.3%	2.2%	1.1%
<u>TOTAL CONSUMER HEALTH</u>					
US	1,611	1,740	-7.4%	-7.4%	-
Intl	1,932	1,885	2.5%	0.5%	2.0%
WW	\$ 3,543	3,625	-2.3%	-3.3%	1.0%

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)

PHARMACEUTICAL SEGMENT ^(2,3)

IMMUNOLOGY

	2021	2020	% Change		
			Reported	Operational ⁽¹⁾	Currency
US	\$ 2,413	2,410	0.1%	0.1%	-
Intl	1,501	1,228	22.3%	15.9%	6.4%
WW	3,914	3,638	7.6%	5.5%	2.1%

REMICADE

US	489	625	-21.7%	-21.7%	-
US Exports ⁽⁴⁾	57	110	-48.4%	-48.4%	-
Intl	232	256	-9.4%	-12.1%	2.7%
WW	777	990	-21.5%	-22.2%	0.7%

SIMPONI / SIMPONI ARIA

US	255	272	-5.9%	-5.9%	-
Intl	307	258	18.9%	13.8%	5.1%
WW	562	529	6.2%	3.7%	2.5%

STELARA

US	1,331	1,217	9.4%	9.4%	-
Intl	817	603	35.6%	27.6%	8.0%
WW	2,148	1,819	18.1%	15.4%	2.7%

TREMFYA

US	274	187	46.3%	46.3%	-
Intl	143	109	32.0%	23.1%	8.9%
WW	418	296	41.0%	37.8%	3.2%

OTHER IMMUNOLOGY

US	7	-	*	*	-
Intl	2	3	-38.4%	-36.3%	-2.1%
WW	8	3	*	*	*

INFECTIOUS DISEASES

US	512	436	17.4%	17.4%	-
Intl	494	483	2.3%	-2.2%	4.5%
WW	1,007	920	9.5%	7.1%	2.4%

COVID-19 VACCINE

US	100	-	*	*	-
Intl	-	-	-	-	-
WW	100	-	*	*	-

EDURANT / rilpivirine

US	10	12	-12.3%	-12.3%	-
Intl	233	212	9.8%	0.9%	8.9%
WW	243	224	8.6%	0.2%	8.4%

PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA

US	380	396	-3.8%	-3.8%	-
Intl	166	184	-9.9%	-10.4%	0.5%
WW	546	579	-5.8%	-5.9%	0.1%

OTHER INFECTIOUS DISEASES

US	21	29	-27.0%	-27.0%	-
Intl	96	87	9.7%	7.4%	2.3%
WW	117	116	0.6%	-1.2%	1.8%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FIRST QUARTER				
	<u>2021</u>	<u>2020</u>	<u>% Change</u>		
			<u>Reported</u>	<u>Operational</u> ⁽¹⁾	<u>Currency</u>
<u>NEUROSCIENCE</u>					
US	771	748	3.2%	3.2%	-
Intl	949	910	4.3%	0.4%	3.9%
WW	<u>1,721</u>	<u>1,658</u>	3.8%	1.6%	2.2%
<u>CONCERTA / Methylphenidate</u>					
US	47	52	-9.6%	-9.6%	-
Intl	123	118	4.5%	-0.4%	4.9%
WW	<u>171</u>	<u>171</u>	0.2%	-3.2%	3.4%
<u>INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA</u>					
US	589	544	8.3%	8.3%	-
Intl	376	339	11.0%	4.5%	6.5%
WW	<u>965</u>	<u>883</u>	9.4%	6.9%	2.5%
<u>RISPERDAL CONSTA</u>					
US	67	76	-11.8%	-11.8%	-
Intl	89	94	-4.8%	-8.8%	4.0%
WW	<u>157</u>	<u>170</u>	-7.9%	-10.1%	2.2%
<u>OTHER NEUROSCIENCE</u>					
US	67	75	-9.8%	-9.8%	-
Intl	361	360	0.2%	-0.9%	1.1%
WW	<u>428</u>	<u>435</u>	-1.5%	-2.5%	1.0%
<u>ONCOLOGY</u>					
US	1,377	1,175	17.2%	17.2%	-
Intl	2,193	1,839	19.3%	12.9%	6.4%
WW	<u>3,570</u>	<u>3,013</u>	18.5%	14.6%	3.9%
<u>DARZALEX</u>					
US	691	463	49.2%	49.2%	-
Intl	674	474	42.2%	35.3%	6.9%
WW	<u>1,365</u>	<u>937</u>	45.6%	42.2%	3.4%
<u>ERLEADA</u>					
US	171	119	44.0%	44.0%	-
Intl	90	24	*	*	*
WW	<u>261</u>	<u>143</u>	82.8%	79.7%	3.1%
<u>IMBRUVICA</u>					
US	444	432	2.8%	2.8%	-
Intl	680	599	13.5%	7.6%	5.9%
WW	<u>1,125</u>	<u>1,031</u>	9.0%	5.6%	3.4%
<u>ZYTIGA / abiraterone acetate</u>					
US	50	139	-64.2%	-64.2%	-
Intl	588	552	6.6%	0.0%	6.6%
WW	<u>638</u>	<u>690</u>	-7.6%	-12.9%	5.3%
<u>OTHER ONCOLOGY</u> ⁽⁵⁾					
US	21	22	-5.1%	-5.1%	-
Intl	161	190	-15.3%	-19.3%	4.0%
WW	<u>182</u>	<u>212</u>	-14.2%	-17.9%	3.7%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FIRST QUARTER				
	<u>2021</u>	<u>2020</u>	% Change		
			<u>Reported</u>	<u>Operational</u> ⁽¹⁾	<u>Currency</u>
<u>PULMONARY HYPERTENSION</u>					
US	573	486	18.0%	18.0%	-
Intl	288	260	10.8%	5.6%	5.2%
WW	<u>861</u>	<u>745</u>	15.5%	13.7%	1.8%
<u>OPSUMIT</u>					
US	272	229	18.5%	18.5%	-
Intl	179	160	11.5%	6.3%	5.2%
WW	<u>450</u>	<u>389</u>	15.6%	13.5%	2.1%
<u>UPTRAVI</u>					
US	259	212	21.9%	21.9%	-
Intl	46	38	23.0%	15.7%	7.3%
WW	<u>305</u>	<u>250</u>	22.0%	20.9%	1.1%
<u>OTHER PULMONARY HYPERTENSION</u>					
US	42	44	-3.5%	-3.5%	-
Intl	63	62	1.4%	-2.1%	3.5%
WW	<u>105</u>	<u>106</u>	-0.6%	-2.7%	2.1%
<u>CARDIOVASCULAR / METABOLISM / OTHER</u>					
US	799	806	-0.9%	-0.9%	-
Intl	328	354	-7.2%	-11.3%	4.1%
WW	<u>1,127</u>	<u>1,160</u>	-2.8%	-4.1%	1.3%
<u>XARELTO</u>					
US	589	527	11.7%	11.7%	-
Intl	-	-	-	-	-
WW	<u>589</u>	<u>527</u>	11.7%	11.7%	-
<u>INVOKANA / INVOKAMET</u>					
US	87	117	-26.1%	-26.1%	-
Intl	63	58	9.2%	4.2%	5.0%
WW	<u>150</u>	<u>175</u>	-14.4%	-16.1%	1.7%
<u>PROCRIT / EPREX</u>					
US	62	76	-18.3%	-18.3%	-
Intl	64	79	-18.1%	-22.2%	4.1%
WW	<u>127</u>	<u>155</u>	-18.2%	-20.3%	2.1%
<u>OTHER</u>					
US	60	85	-28.8%	-28.8%	-
Intl	201	217	-7.7%	-11.5%	3.8%
WW	<u>261</u>	<u>302</u>	-13.6%	-16.4%	2.8%
<u>TOTAL PHARMACEUTICAL</u>					
US	6,446	6,061	6.4%	6.4%	-
Intl	5,753	5,073	13.4%	7.9%	5.5%
WW	<u>\$ 12,199</u>	<u>11,134</u>	9.6%	7.1%	2.5%

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)

MEDICAL DEVICES SEGMENT ⁽²⁾

INTERVENTIONAL SOLUTIONS

	<u>2021</u>	<u>2020</u>	<u>% Change</u>		
			<u>Reported</u>	<u>Operational ⁽¹⁾</u>	<u>Currency</u>
US	\$ 434	365	19.0%	19.0%	-
Intl	514	362	42.0%	34.0%	8.0%
WW	<u>949</u>	<u>727</u>	30.4%	26.4%	4.0%

ORTHOPAEDICS

US	1,249	1,250	-0.1%	-0.1%	-
Intl	864	788	9.7%	3.1%	6.6%
WW	<u>2,113</u>	<u>2,038</u>	3.7%	1.2%	2.5%

HIPS

US	210	206	2.4%	2.4%	-
Intl	146	132	11.2%	4.5%	6.7%
WW	<u>357</u>	<u>337</u>	5.8%	3.2%	2.6%

KNEES

US	185	214	-13.5%	-13.5%	-
Intl	132	130	2.0%	-4.1%	6.1%
WW	<u>317</u>	<u>343</u>	-7.6%	-9.9%	2.3%

TRAUMA

US	450	407	10.7%	10.7%	-
Intl	282	247	14.4%	7.7%	6.7%
WW	<u>733</u>	<u>654</u>	12.1%	9.5%	2.6%

SPINE, SPORTS & OTHER

US	403	423	-4.8%	-4.8%	-
Intl	303	280	8.4%	1.7%	6.7%
WW	<u>706</u>	<u>703</u>	0.4%	-2.2%	2.6%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FIRST QUARTER				
	2021	2020	% Change		
			Reported	Operational ⁽¹⁾	Currency
<u>SURGERY</u>					
US	898	844	6.5%	6.5%	-
Intl	1,474	1,257	17.3%	11.7%	5.6%
WW	<u>2,372</u>	<u>2,100</u>	12.9%	9.6%	3.3%
<u>ADVANCED</u>					
US	405	381	6.5%	6.5%	-
Intl	713	567	25.7%	19.5%	6.2%
WW	<u>1,118</u>	<u>948</u>	18.0%	14.3%	3.7%
<u>GENERAL</u>					
US	493	463	6.5%	6.5%	-
Intl	761	690	10.3%	5.3%	5.0%
WW	<u>1,254</u>	<u>1,153</u>	8.8%	5.8%	3.0%
<u>VISION</u>					
US	472	439	7.4%	7.4%	-
Intl	673	628	7.3%	3.9%	3.4%
WW	<u>1,145</u>	<u>1,067</u>	7.3%	5.4%	1.9%
<u>CONTACT LENSES / OTHER</u>					
US	371	346	7.2%	7.2%	-
Intl	486	467	4.0%	0.9%	3.1%
WW	<u>857</u>	<u>814</u>	5.3%	3.5%	1.8%
<u>SURGICAL</u>					
US	101	93	8.2%	8.2%	-
Intl	187	160	17.0%	12.9%	4.1%
WW	<u>288</u>	<u>253</u>	13.7%	11.2%	2.5%
<u>TOTAL MEDICAL DEVICES</u>					
US	3,054	2,898	5.4%	5.4%	-
Intl	3,525	3,034	16.2%	10.5%	5.7%
WW	<u>\$ 6,579</u>	<u>5,932</u>	10.9%	8.0%	2.9%

Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

* Percentage greater than 100% or not meaningful

(1) Operational growth excludes the effect of translational currency

(2) Unaudited

(3) Certain prior year amounts have been reclassified to conform to current year product disclosures

(4) Reported as U.S. sales

(5) Refer to supplemental schedule

Supplemental Sales Information
(Dollars in Millions)

Prior quarter amounts have been reclassified to conform to current quarter product disclosure

	2019	2020				2020
	<u>Full Year</u>	<u>Q1</u>	<u>Q2</u>	<u>Q3</u>	<u>Q4</u>	<u>Full Year</u>
<u>PHARMACEUTICAL SEGMENT</u> ⁽¹⁾						
<u>Oncology</u>						
<u>OTHER ONCOLOGY</u> ⁽²⁾						
US	70	22	20	21	20	83
Intl	<u>1,087</u>	<u>190</u>	<u>185</u>	<u>181</u>	<u>183</u>	<u>738</u>
WW	<u>1,158</u>	<u>212</u>	<u>204</u>	<u>203</u>	<u>202</u>	<u>821</u>

Note: Columns and rows within tables may not add due to rounding.

(1) Unaudited

(2) Other Oncology is inclusive of VELCADE, which was previously disclosed separately